Searchable abstracts of presentations at key conferences in obesity

ob0002cd2.1 | Case Discussions: Complex Clinical Cases 2 | OU2020

Obstructive sleep apnoea is highly prevalent in a bariatric surgical population

Agius Rachel , Coelho Claudia , Crane James , Gupta Piya Sen , McGowan Barbara

Background: Obesity is an important predictor for development of obstructive sleep apnoea (OSA). Patients undergoing bariatric surgery are at increased risk of peri-operative morbidity from undiagnosed OSA. We aim to assess the prevalence and severity of OSA, and its association with the Epworth Screening Scale (ESS) in a bariatric surgical population.Methods: Retrospective study of adult patients who attended the Tier 4 Medical Obesity Clinic (MOC) at G...

ob0003cd2.1 | Case Discussions 2 | OU2021

Contribution of BMI to ethnic disparities in outcomes following hospitalisation for COVID-19

Badawy Layla , Crane James , Sparks Rachel , Quinn Mark , Whyte Martin , McGowan Barbara

Background: Ethnicity and obesity have been recently established as risk factors for adverse coronavirus disease 19 (COVID-19) outcomes. The prevalence of obesity differs across ethnic groups. Thus, previously reported ethnic differences in COVID-19 outcomes may be due to underlying variations in BMI.Aims: To investigate the association between ethnicity and in-hospital mortality in COVID-19, and the effect of BMI. The secondary aim was to investigate th...

ob0004p11 | Presented Posters | OU2024

Post-bariatric surgery hypoglycaemia: Challenging cases in the Medical Obesity Clinic

D Boyle Luke , Sen Gupta Piya , Coelho Claudia , McGowan Barbara M

Introduction: Post-bariatric surgery hypoglycaemia (BPH) is a metabolic complication of bariatric surgery, which may develop months or years post-procedure and is encountered increasingly frequently in obesity medicine. We present a case series from our large Tier 4 service, illustrating the challenges posed when diagnosing and managing this condition.Case 1: 51F with a history of obesity (BMI 55, weight 159kg) and Roux-...

ob0004p6 | Presented Posters | OU2024

The Roczen programme: Real-world data of a digitally enabled time restrictive eating programme on biometric outcomes in an ethnically diverse population in the UK

Falvey Laura , Dobbie Laurence , Chow Ling , Ashton Claudia , Brown Adrian , Patel Dipesh , Kwan Jonathan , Steinmo Siri , McGowan Barbara

Introduction: Roczen is a digital, clinical programme designed for people living with obesity (PLwO) and complications such as type 2 diabetes (T2D) that utilises time-restricted eating (TRE). Weight management and metabolic health intervention data mostly includes people from white ethnicity. The aim was to examine the impact of the programme in an ethnically diverse population in the UK at 12 months (12m).Method: We co...

ob0004p3 | Presented Posters | OU2024

Proposed prioritisation framework for the introduction of new medical therapies for weight management in the NHS

Boyle Luke D , Albor Christo , Anyiam Oluwaseun , Sen Gupta Piya , Coelho Claudia , Crane James , K Dimitriadis Georgios , Andrews Robert , Hughes David , Idris Iskandar , Tan Tricia , M McGowan Barbara , McCullough Kath

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...